Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists?
[New treatment options in multiple sclerosis and their complications].
Progressive multiple sclerosis and mood disorders.
Neutralizing Antibodies Are Associated with a Reduction of Interferon-β Efficacy during the Treatment of Japanese Multiple Sclerosis Patients.
Comprehension and Data-Sharing Behavior of Direct-To-Consumer Genetic Test Customers.
Brain MRI of nasal MOG therapeutic effect in relapsing-progressive EAE.
HMG-CoA reductase inhibitors reduce adhesion of human monocytes to endothelial cells.
Incidence and prevalence of multiple sclerosis in southeastern Iran.
Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models.
Neurocardiogenic Pulmonary Oedema: Initial Presentation of Multiple Sclerosis.
The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
Progressive multifocal leukoencephalopathy in a patient with chronic lymphocytic leukaemia treated with alemtuzumab.
Novel immunoregulatory properties of EGCG on reducing inflammation in EAE.
siRNA knockdown of ADAM-10, but not ADAM-17, significantly reduces fractalkine shedding following pro-inflammatory cytokine treatment in a human adult brain endothelial cell line.
Multiple sclerosis and vitamin D during pregnancy and lactation.
Effects of inoculation with attenuated autologous T cells in patients with rheumatoid arthritis.
Gait variability and disability in multiple sclerosis.
Dimethyl fumarate - only an anti-psoriatic medication?
Effects of physiotherapy interventions on balance in multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials.
[Emerging therapies for multiple sclerosis.]
[Transorbital echography for assessment of optical nerve atrophy in demyelinating diseases: a pilot study].
Fenofibrate Inhibited the Differentiation of T Helper 17 Cells In Vitro.
Alcohol as a Modifiable Lifestyle Factor Affecting Multiple Sclerosis Risk.
Tumefactive demyelination: an approach to diagnosis and management.
Neuropathic pruritus (itch) in neuromyelitis optica.
Pages
« first
‹ previous
…
195
196
197
198
199
200
201
202
203
…
next ›
last »